Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
33 Keratoconus Trials
Power is an online platform that helps thousands of Keratoconus patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Plasma Tear Drops for Dry Eye Syndrome
Rochester, New YorkThis is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
15 Participants Needed
TTAX03 for Dry Eye Syndrome
Shelby, North CarolinaThe purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED.
The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness.
Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness.
Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Corneal Ectatic Disorder, Severe Blepharitis, Severe Conjunctivochalasis, Others
Must Not Be Taking:Nasal Cholinergics, Glaucoma Meds
72 Participants Needed
AR-15512 for Dry Eye Syndrome
Fort Worth, TexasThe purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
79 Participants Needed
Ocular Lubricant for Dry Eye Syndrome
Pittsburg, KansasThe purpose of this study is to evaluate and demonstrate the efficacy and safety of an investigational ocular lubricant formulation in patients with mild to moderate dry eye disease (DED).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
185 Participants Needed
Miebo for Dry Eye Syndrome
Kansas City, MissouriA Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
216 Participants Needed
Cornea Crosslinking for Keratoconus
Boca Raton, FloridaThis study study is to determine the effectiveness of cornea cross linking in patients with Keratoconus or other cornea thinning conditions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Infections, Collagen Vascular Disease, Pregnancy, Others
300 Participants Needed
Reproxalap for Dry Eye Syndrome
Andover, MassachusettsA Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
110 Participants Needed
AZR-MD-001 for Dry Eye Syndrome
St. Louis, MissouriThis study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
500 Participants Needed
Reproxalap for Dry Eye Syndrome
Shelby, North CarolinaA Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
400 Participants Needed
Cyclosporine + Intense Pulsed Light for Dry Eye Syndrome
Sherbrooke, QuebecIn this study, two treatments typically used for dry eye disease will be tried for contact lens users to see if their symptoms when they use their contact lenses get better. Cyclosporine is a drop that is used for long-term management of the inflammation and Intense pulsed light (IPL) is a treatment done in a clinic to improve the health of the eyelid glands. The main question in this study is:
Does the combined treatment of cyclosporine and IPL improve the symptoms and the dry eye signs of contact lens wearers?
All the participants will receive the cyclosporine drops for 4 months twice a day. The research team will split the group of participants in two, half receiving the real IPL treatment and half receiving a sham IPL treatment during the last two months of the study. This will allow to compare the two groups to see how IPL helped. The dry eye tests will be done at the start of the study, after two months and after 4 months. The tests will include a dry eye symptoms questionnaire, measures on the tears, the structures of the front of the eye and the eyelids.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Ocular Herpes, Epilepsy, Others
Must Be Taking:Cyclosporine
44 Participants Needed
Corneal Cross-Linking for Keratoconus
Boston, MassachusettsThis randomized clinical trial will assess corneal astigmatism and visual outcomes in participants who have undergone corneal transplantation for keratoconus with ex vivo cross-linked donor corneal tissue versus participants who have undergone corneal transplantation for keratoconus with non-cross-linked donor corneas. Crosslinking is a procedure that stabilizes the biomechanical properties of the cornea; as a result, the cornea stiffens. It has been shown that this procedure stabilizes the cornea of patients with keratoconus or corneal ectasias. The FDA currently approves crosslinking for patients with progressive keratoconus and corneal ectasia following refractive surgery. Ex vivo crosslinking of donor corneal tissue for patients with keratoconus undergoing PK or DALK could stabilize the cornea and reduce the risk of high astigmatism and improve vision in patient with keratoconus.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:All
216 Participants Needed
Light Therapy + MGX for Dry Eye Disease
Miami, FloridaClinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Contact Lenses, Ocular Surgery, Uncontrolled Infections, Others
Must Not Be Taking:Photosensitizing Drugs
100 Participants Needed
Corneal Cross-Linking for Keratoconus
Westerville, OhioThis trial is testing a treatment that uses light and vitamins to strengthen the cornea in people with keratoconus, a condition that makes the cornea thin and cone-shaped. The new treatment option aims to improve the cornea's strength and shape.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Allergy, Abnormal Topography, Ocular Condition
150 Participants Needed
Levocarnitine for Dry Eye in Sjogren's Syndrome
Nashville, TennesseeThis trial tests levocarnitine, a supplement that helps transport carnitine into cells, in adults with Sjogren's syndrome who have dry eyes. Sjogren's syndrome causes dryness in the eyes and mouth. Levocarnitine may help by increasing carnitine levels in tears, potentially reducing eye dryness and improving comfort. Levocarnitine is a molecule required in mammalian energy metabolism, facilitating the transport of long-chain fatty acids across the mitochondrial membrane for energy production.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 75
Sex:All
15 Participants Needed
Corneal Collagen Crosslinking for Keratoconus
Teaneck, New JerseyCorneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies.
Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Corneal Disease, Pregnancy, Nystagmus, Others
170 Participants Needed
Corneal Gas Permeable Lenses for Keratoconus
Chicago, IllinoisKeratoconus is a non-inflammatory, progressive disease in which corneal irregularity increases. As the condition develops, more advanced forms of optical correction are needed to improve vision for patients. Until recently, small diameter corneal gas permeable lenses were considered the primary mode of correction for patients with keratoconus. Now, however, practitioners have multiple options for reducing the optical aberrations caused by keratoconus, including scleral lenses. As of yet, no single option for optical correction has been identified as the preferred mode of correction in terms of overall patient satisfaction with vision, comfort, and ease of use. The order in which various forms of optical correction would be most logically introduced has yet to be determined. This is a study comparing small diameter corneal gas permeable and large diameter scleral lenses in individuals with keratoconus.
This study will prospectively compare visual satisfaction and ease of use between corneal gas permeable and scleral lenses for patients with mild to moderate keratoconus.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
32 Participants Needed
Corneal Collagen Crosslinking for Keratoconus
Teaneck, New JerseyCorneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Corneal Disease, Pregnancy, Nystagmus, Others
160 Participants Needed
Corneal Collagen Crosslinking for Keratoconus
Teaneck, New JerseyThis study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Corneal Disease, Pregnancy, Nystagmus, Others
170 Participants Needed
Wavefront Guided Scleral Lenses for Keratoconus and Astigmatism
Teaneck, New JerseyThis trial is testing special contact lenses for people with severe vision issues that regular lenses can't fix. These custom-made lenses use advanced eye measurements to improve vision quality by correcting specific distortions.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
100 Participants Needed
Dupilumab for Conjunctivitis
Pittsburg, KansasThis is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
42 Participants Needed
Corneal Cross-Linking for Keratoconus
San Francisco, CaliforniaThis trial is testing a device called the PXL Platinum 330 system, which uses a special light treatment to strengthen the cornea. It targets patients with conditions that weaken and misshape the cornea, such as progressive keratoconus and pellucid marginal degeneration. The treatment works by creating new connections between the fibers in the cornea, helping it stay strong and maintain its shape.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:10+
Sex:All
Key Eligibility Criteria
Disqualifiers:Normal Eyes, Corneal Disease, Pregnancy, Others
500 Participants Needed
Eye Drops for Dry Eye Syndrome
Boston, MassachusettsThis is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: Hypertonic Saline Non-Responders (33 subjects) and Hypertonic Saline Responders (33 subjects). After completion of questionnaires, the subjects will undergo Dry Eye Disease testing and functional nerve testing. Subjects who qualify will be dispensed 4 weeks of preservative free artificial tears and instructed to instill one drop into each eye twice daily. Subjects will return for a follow up visit 4 weeks later (± 4 days), during which subjects will complete the questionnaires again and the Dry Eye Disease tests and functional nerve tests will be repeated.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Centralized Pain, Ocular Surgery, Others
Must Not Be Taking:Topical Treatments
66 Participants Needed
Corneal Collagen Cross-Linking for Keratoconus
Eugene, OregonTo determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:12 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Corneal Disease, Nystagmus, Others
300 Participants Needed
Standard vs. Accelerated Corneal Crosslinking for Keratoconus
Indianapolis, IndianaThis trial compares two methods of corneal crosslinking, a procedure that strengthens the cornea using special eye drops and light. It targets people with progressive keratoconus or corneal ectasia, conditions where the cornea weakens and bulges out. The treatment aims to make the cornea more stable and prevent further vision problems. Corneal crosslinking (CXL) has become the standard treatment for rapidly progressing keratoconus.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:10+
Sex:All
Key Eligibility Criteria
Disqualifiers:Insufficient Corneal Thickness, Pregnancy, Others
510 Participants Needed
Corneal Collagen Cross-Linking Techniques for Keratoconus
Sacramento, CaliforniaThis is a prospective, randomized, single investigative site study to compare the safety and effectiveness of Epi-OFF CXL treatment (performed using Ricrolin+ and VEGA UV-A system) compared to Epi-ON CXL (performed using Ricrolin+ and VEGA UV-A system) in eyes with keratoconus and other corneal ectatic disorders.Subjects will be randomized to receive the CXL treatment with either the Epi-On or Epi-Off technique.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
550 Participants Needed
Corneal Collagen Cross-Linking for Keratoconus
Portland, OregonThis trial uses a special laser treatment with precise scanning and medication to improve vision in patients with keratoconus by strengthening and smoothing their corneas.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Diseases, Glaucoma, Cataracts, Others
100 Participants Needed
Riboflavin for Keratoconus
Columbia, MissouriThis trial tests if taking vitamin B2 pills and spending time in the sun can help strengthen the cornea in patients with certain eye conditions. The goal is to provide a less painful and cheaper alternative to current treatments. A method using vitamin B2 and sunlight has been developed since the late 1990s to strengthen the cornea in these conditions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Riboflavin Sensitivity, Sunlight Sensitivity, Others
Must Not Be Taking:Sunlight Sensitivity Drugs
24 Participants Needed
Corneal Crosslinking for Keratoconus
Boise, IdahoThis study will investigate the effectiveness in treating keratoconus, pellucid marginal degeneration and post LASIK iatrogenic ectasia utilizing fluence rates and treatment times of Corneal Cross Linking other than the original FDA approved protocol of 3mw/cm2.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:15 - 50
Sex:All
100 Participants Needed
Corneal Tissue Inlay for Keratoconus
Teaneck, New JerseyThis study will evaluate the outcomes of placing preserved corneal tissue within the keratoconic cornea in order to enhance thickness, stability, and optical conformation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
20 Participants Needed
Corneal Collagen Crosslinking for Keratoconus
Teaneck, New JerseyCorneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During previous studies of the CXL procedure, the surface epithelial cells have been removed. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection as no epithelial barrier will be broken, faster visual recovery and improved patient comfort in the early postoperative healing period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
160 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Keratoconus clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Keratoconus clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Keratoconus trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Keratoconus is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Keratoconus medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Keratoconus clinical trials ?
Most recently, we added Plasma Tear Drops for Dry Eye Syndrome, TTAX03 for Dry Eye Syndrome and AR-15512 for Dry Eye Syndrome to the Power online platform.
Related Searches
By Condition
Popular Searches
By Condition